» Articles » PMID: 30003321

Interactions Among Myeloid Regulatory Cells in Cancer

Abstract

Mounting evidence has accumulated on the critical role of the different myeloid cells in the regulation of the cancerous process, and in particular in the modulation of the immune reaction to cancer. Myeloid cells are a major component of host cells infiltrating tumors, interacting with each other, with tumor cells and other stromal cells, and demonstrating a prominent plasticity. We describe here various myeloid regulatory cells (MRCs) in mice and human as well as their relevant therapeutic targets. We first address the role of the monocytes and macrophages that can contribute to angiogenesis, immunosuppression and metastatic dissemination. Next, we discuss the differential role of neutrophil subsets in tumor development, enhancing the dual and sometimes contradicting role of these cells. A heterogeneous population of immature myeloid cells, MDSCs, was shown to be generated and accumulated during tumor progression as well as to be an important player in cancer-related immune suppression. Lastly, we discuss the role of myeloid DCs, which can either contribute to effective anti-tumor responses or play a more regulatory role. We believe that MRCs play a critical role in cancer-related immune regulation and suggest that future anti-cancer therapies will focus on these abundant cells.

Citing Articles

The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy.

Li G, Che X, Wang S, Liu D, Xie D, Jiang B Ann Med. 2025; 57(1):2447403.

PMID: 39757995 PMC: 11705547. DOI: 10.1080/07853890.2024.2447403.


Trial watch: anticancer vaccination with dendritic cells.

Borges F, Laureano R, Vanmeerbeek I, Sprooten J, Demeulenaere O, Govaerts J Oncoimmunology. 2024; 13(1):2412876.

PMID: 39398476 PMC: 11469433. DOI: 10.1080/2162402X.2024.2412876.


Characterization of myeloid-derived suppressor cells in the peripheral blood and bone marrow of patients with chronic idiopathic neutropenia.

Bizymi N, Damianaki A, Aresti N, Karasachinidis A, Vlata Z, Lavigne M Hemasphere. 2024; 8(9):e70005.

PMID: 39315322 PMC: 11417472. DOI: 10.1002/hem3.70005.


Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by F-BMS986-192 PET: pooled analysis of data from four solid tumor types.

Miedema I, Pouw J, Kwakman A, Zwezerijnen G, Huisman M, Timmer F J Immunother Cancer. 2024; 12(6).

PMID: 38886117 PMC: 11184194. DOI: 10.1136/jitc-2024-008899.


CD40 Ligand-CD40 Interaction Is an Intermediary between Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy.

Abu El-Asrar A, Nawaz M, Ahmad A, Dillemans L, Siddiquei M, Allegaert E Int J Mol Sci. 2023; 24(21).

PMID: 37958563 PMC: 10648257. DOI: 10.3390/ijms242115582.


References
1.
Hoshino A, Costa-Silva B, Shen T, Rodrigues G, Hashimoto A, Mark M . Tumour exosome integrins determine organotropic metastasis. Nature. 2015; 527(7578):329-35. PMC: 4788391. DOI: 10.1038/nature15756. View

2.
Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J . Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One. 2013; 8(2):e57114. PMC: 3577767. DOI: 10.1371/journal.pone.0057114. View

3.
Spranger S, Dai D, Horton B, Gajewski T . Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017; 31(5):711-723.e4. PMC: 5650691. DOI: 10.1016/j.ccell.2017.04.003. View

4.
Templeton A, McNamara M, Seruga B, Vera-Badillo F, Aneja P, Ocana A . Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106(6):dju124. DOI: 10.1093/jnci/dju124. View

5.
Ginhoux F, Guilliams M . Tissue-Resident Macrophage Ontogeny and Homeostasis. Immunity. 2016; 44(3):439-449. DOI: 10.1016/j.immuni.2016.02.024. View